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Spinal muscular atrophy (SMA) is a neurodegenerative disease 
characterized by progressive muscle wasting, loss of motor 
function and premature death in the most severe cases.1-3 Two 
genes, SMN1 and SMN2, produce survival motor neuron (SMN) 
protein,4-6 which is ubiquitously expressed with the highest levels 
in the spinal cord7 and functions in the assembly of spliceosomal 
small nuclear ribonucleoproteins.8 The majority of SMN protein 
normally is produced from the SMN1 gene, while the almost 
identical SMN2 gene only produces approximately 10% of 
functional protein.9,10  
SMA results from mutations within exon 7 of SMN1, leading to 
SMN protein deficiency.11 The clinical severity of this disease is, 
therefore, indirectly proportional to the copy number of SMN2 
genes, the sole source of protein in these patients.12,13 Although 
the threshold level of SMN protein necessary to maintain healthy 
motor neurons is not known, it has been estimated that increasing 
the amount of functional protein by only 2- or 3-fold may be 
clinically significant.14 Thus, the SMN2 gene has become a 
therapeutic target, in which multiple strategies (i.e., small 
molecules, antisense oligonucleotide) work to increase the 
transcription of SMN2, increase the inclusion of exon 7 SMN2, 
stabilize the full-length exon-7 included SMN2 mRNA, or 
stabilize the SMN protein.15-17 As SMA is the leading heritable 
cause of infant mortality, it is critical to build upon the one 
recently FDA-approved treatment, Nusinersen, an antisense 
oligonucleotide18 and to provide a variety of treatment options 
with different modes of action.  Several repurposed drugs, such 
as riluzole, phenylbutyrate, valproic acid, albuterol and 
hydroxyurea, have advanced into clinical trials, but none has 
elicited convincing improvement in muscle function or survival 
in SMA.  Currently, there are several small molecules in Phase I 
to Phase III clinical trials for SMA, including compounds that 
increased exon 7 inclusion of SMN2.19 
Previously, we reported an SMN2-lucifrase reporter assay for 
identifying compounds that increase SMN expression from the 
SMN2 gene and its use in high-throughput screening.20 Using the 
reporter assay, we discovered two hit compounds, LDN-75654 
(1) and LDN-76070 (2) (Figure 1), that increase expression of 
SMN2 by 2-fold, but that have different mechanisms of action 
than the small molecules already in clinical trials to treat SMA. 
Compound 1 increases the stability of SMN protein, whereas 
compound 2 acts in a transcriptional manner.21
We recently reported the structure-activity relationship (SAR) of 
analogs of the 5-isopropylisoxazole-3-carboxamide 1.22 In this 
paper, we report preliminary SAR of the 3,4-dihydro-4-phenyl-
2(1H)-quinolinone 2 for increasing SMN expression. 
Figure 1. Two SMN mRNA expression enhancers identified 
following high-throughput screening. 
The 3,4-dihydro-4-phenyl-2(1H)-quinolinone derivatives were 
prepared according to the procedure outlined in Scheme 1. A 
three-component coupling of an aniline (3), aromatic aldehyde 
(4) and Meldrum’s acid in refluxing ethanol generated the 
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Spinal muscular atrophy (SMA) is a neurodegenerative disorder that results from mutations in the SMN1 gene, leading to 
survival motor neuron (SMN) protein deficiency. One therapeutic strategy for SMA is to identify compounds that enhance 
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quinolinones 5a-m in good yield.23 These compounds were 
transformed further into the methyl substituted derivatives 6a-b, 
which were isolated as mixture of cis- and trans-isomers. 
Scheme 1. (a) Meldrum’s acid, EtOH, 85ºC, 16 h (55-78%); (b) 
BuLi, THF, 0ºC then MeI (48%). 
A series of 3,4-dihydro-quinazolinone derivatives 9a-9l was 
prepared according to the procedures outlined in Scheme 2.24 
Anilines 3 were treated with potassium isocyanate to give the 
ureas 8 (e.g., R = H). Alternatively, phenyl isocyanates 7 were 
treated with primary amines to yield substituted ureas 8 (e.g., R = 
alkyl).  The ureas then were treated with catalytic methane 
sulfonic acid in refluxing toluene, with azeotropic removal of 
water, to produce the 3,4-dihydro-quinazolinones 9a-9r. 
Scheme 2. (a) KNCO, AcOH, RT; (84-97%); (b) RNH2, THF, 0 ºC 
to RT (63-89%); (c) R2PhCHO, cat. MeSO3H, toluene, reflux (31-
81%). 
The synthesis of the 2-quinazolinone 13 and the seven-membered 
1,4-benzodiazepin-2-one 14 is outlined in Scheme 3.  The 
pivolate-protected 3,4,5-trimethoxylaniline 10 was lithiated with 
butyllithium in THF at -78oC, and the resulting anion was 
quenched with methyl 5-chloro-2-fluorobenzoate to give the 
ketone 11 in modest yield. The pivolate group was cleaved with 
refluxing sulfuric acid and gave the versatile intermediate 12. For 
example, the ketone 12 was treated with trichloroacetyl chloride, 
and the product, upon treatment with ammonium acetate, 
cyclized to 13.  On the other hand, the ketone 12 also was treated 
with glycine ethyl ester, with azeotropic removal of water, and 
gave the 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 14.  
Scheme 3. (a) BuLi, THF -78oC then methyl 5-chloro-2-
fluorobenzoate (15%); (b) H2SO4, EtOH, reflux (57%); (c) 
Cl3CCOCl, DCM, Et3N, RT; (d) NH4OAc, DMSO, 80ºC (41% over 
2-steps); (e) HCl•NH2CH2CO2Et, Py, Dean-Stark trap, reflux, 24 h 
(38%). 
Several oxygen-containing heterocycles (e.g., 16, 19-21) also 
were prepared from the ketone 12 (Scheme 4 and Scheme 5). 
Ketone 12 was reduced to the racemic alcohol 15 with sodium 
borohydride in ethanol. Treatment of 15 with carbonyl 
diimidazole (CDI) directly gave the oxazinone 16 in good yield. 
Acylation of 15 with 2-bromoacetyl chloride or 2-
bromopropionyl chloride gave the amides 17 and 18, 
respectively. Treatment of 17 with two equivalents of sodium 
hydride gave the 7-membered benzoxazepin-2(3H)-one 19 in 
moderate yield.25 Similarly, cyclization of 18 gave the 3-methyl-
benzoxazepin-2(3H)-one 20 as a mixture of diastereoisomers. 
Finally, treatment of 19 with methyl iodide gave the N-methyl 
amide 21. 
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Scheme 4. (a) NaBH4, EtOH, RT (82%); (b) CDI, THF, RT (76%); 
(c) BrCHRC(O)Cl, Et2O, Et3N, 0ºC to RT (62-73%); (d) NaH, THF, 
RT then reflux (43-72%); (e) MeI, Cs2CO3, THF, RT (81%). 
The synthesis of the 5-methyl substituted benzoxazepinone 23 is 
outlined in Scheme 5. Treatment of the ketone 12 with methyl 
magnesium bromide gave the racemic tertiary alcohol 22 in good 
yield. Reaction of 22 with 2-bromoacetyl chloride and cyclization 
gave 23. 
 
Scheme 5. (a) MeMgBr, THF, 0oC (67%); (b) BrCH2C(O)Cl, Et2O, 
Et3N, 0ºC to RT; (c) NaH, THF, RT then reflux (54% over 2-steps). 
Compounds were assessed for activity in the luciferase reporter 
assay, as previously described, at various concentrations (0.1 – 
50 µM), and were compared to DMSO (0.1%) controls.19 Dose-
response curves were generated to determine EC50 values and 
percent maximum increase in SMN2 expression. Unless 
otherwise stated, all values are the mean ± S.E.M. of 3 separate 
experiments.  First, the importance of the tri-methoxy group on 
the aryl ring and methyl substitution at each of the 1- and 3-
positions of the dihydro-quinolinone was investigated (Figure 2).  
Removal of either the 7- or 6-methoxy group (e.g., compounds 
5a and 5b) resulted in the complete loss of activity. With this 
information, the methoxy groups were determined to be 
necessary for activity, and the tri-methoxy group was retained in 
the remaining analogs described in this optimization study.  
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Similarly, the 1- and 3-methyl analogs (e.g., 6a and 6b) were 
inactive, and these two positions were left unsubstituted in 
subsequent analogs. 
Figure 2. Effects of deletion of individual methoxy substituents and 
methyl substitution to the dihydro-quinolinone core. 
We next investigated the effects on SMN2 expression of 
substituents on the 4-aryl ring (Table 1). Compounds were 
prepared following the cyclization procedure outlined in Scheme 
1.  Removal of either the 5-bromo (e.g., 5c) or the 2-flouro (e.g., 
5d) led to a complete loss in activity, indicating the importance 
of a substituent at both positions.  Therefore, we retained the 2-
flouro substituent and varied the 5-substituent. Replacing the 5-
bromo by 5-chloro gave an analog (5e) of similar activity to 2, 
but other electron withdrawing groups were not active (e.g., 5f, 
5g, 5h and 5i). Several other halogenated analogs also were 
found to be inactive (e.g., 5j, 5k, 5l and 5m). 
Table 1. Effects of substitution on the aryl ring of the 3,4-
dihydro-4-aryl- 2(1H)-quinolinone 
core. 
 
 
 
# Ar EC50 (µM) # Ar EC50 (µM) 
2 2-F,5-Br 8.3 (186%) 5c 2-F IA 
5d 3-Br IA 5e 2-F,5-Cl 12 (150%) 
5f 2-F,5-F IA 5g 2-F,5-CN IA 
5h 2-F,5-NO2 IA 5i 2-F,5-
CONH2 
IA 
5j 2-Cl,3-Cl IA 5k 2-Cl,4-Cl IA 
5l 3-F,4-F IA 5m 3-Cl,4-Cl IA 
After the disappointing finding that limited substitution was 
tolerated on the 4-aryl ring, we chose to explore other cyclic 
cores. The goal was to identify a more potent core and then to 
revisit the SAR on the 4-aryl ring. Although the 5-bromo-2-
fluoro aryl analog 2 was the most active compound, for chemical 
stability reasons, we chose to retain the 5-chloro-2-fluoro aryl 
ring at the benzylic position of the new cores (Table 2). The 3,4-
dihydro-quinazolinone derivative 9a had very promising activity, 
although the N-methyl (9b) was less active, and both the N-
propyl (9c) and the 2-quinazolinone (13) were inactive. The 
seven-membered benzodiazepin-2-one 14 retained potency 
similar to the lead 2, although its efficacy was reduced. Several 
of the oxygen containing heterocycles had interesting activity.  
The benzoxazin-2-one 16 had encouraging activity, and the 7-
membered benzoxazepin-2(3H)-ones, 19 and 20, had similar 
activities as 9a.  Interestingly, the 3-methyl analog 20 was tested 
as a mixture of diastereoisomers, and it is likely that one isomer 
will retain all activity. N-Methylation of the amide (21) was not 
tolerated, and introduction of a methyl group at the benzylic 
position (e.g., 23) also was not tolerated. 
Table 2. Effects of the heterocyclic core (Ar = 2-F,5-Cl-phenyl) 
# Compound # Compound 
 
9a 
 EC50 = 4.1 µM (263%) 
 
9b 
 EC50 = 6 µM (180%) 
 
9c 
Inactive 
 
13 
 Inactive 
 
14 
 
EC50 = 8.4 (125%) 
 
16 
 EC50 =? (125%) 
 
19 
EC50 = 5.9 (150%) 
 
20 
 EC50 = 2.6 (125%) 
 
21 
Inactive 
 
23 
Inactive 
Given the promising activity of the 3,4-dihydro-quinazolinone 
core (e.g., 9a), we evaluated the SAR for aryl substitution with 
this heterocyclic core (Table 3). Removal of either the 5-chloro 
(e.g., 9b) or the 2-flouro (e.g., 9c) led to a partial, but not a 
complete, loss in activity. Other mono-halogenated analogs 
retained some activity (e.g., 9d, 9e and 9g), although the 
methoxy analogs (9h-9j) were inactive. In the next set of analogs, 
the 2-fluoro substituent was retained, and the 5-substituent was 
varied. The 5-methyl analog 9k had similar potency, and the 5-
fluoro 9n was less active. The other 5-substituted analogs (9l, 9m 
and 9o) were inactive but moving the 5-chloro to the 4-position 
(9p) was tolerated.  Although the 2-methoxy analog (9h) activity 
was restored on incorporation of a 4-chloro (9q) or 5-chloro (9r).  
Table 3. Effects of substitution on the aryl ring of the 3,4-
dihydro-4-aryl- quinazolin-2(1H)-one 
core. 
 
 
 
# Ar EC50 (µM) # Ar EC50 (µM) 
9a 2-F,5-Cl 4.1 (263%) 9b 2-F 10 (100%) 
9c 3-Cl 5.2 (100%) 9d 3-F 25 (150%) 
9e 4-F 14.0 (150%) 9f 2-Cl IA 
9g 4-Cl 6.6 (150%) 9h 2-OMe IA 
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9i 3-OMe 18 (100%) 9j 4-OMe IA 
9k 2-F,5-Me 4.3 (125%) 9l 2-F,5-Ph IA 
9m 2-F,5-CN IA 9n 2-F,5-F 17 (100%) 
9o 2-F,5-OMe IA 9p 2-F,4-Cl 6.3 (150%) 
9q 2-OMe,4-Cl 7.8 (200%) 9r 2-OMe,5-Cl 3.6 (225%) 
In the preliminary SAR of the quinazolinone series, we did not 
establish the importance of the 5-methoxy group on SMN 
enhancing activity (e.g., deletion of the 5-OMe).  We did, 
however, establish the importance of a methoxy group at the 
analogous position in the benzoxazepin-2(3H)-one series. The 
synthesis of 26 is outlined in Scheme 6. Palladium-catalyzed 
addition of the commercially available 5-chloro-2-
fluorophenylboronic acid and 2-amino-4,5-dimethoxybenzonitril
e 24 gave the corresponding ketone, which then was reduced with 
sodium borohydride in ethanol to give the racemic alcohol 25. 
Reaction of 25 with 2-bromoacetyl chloride, and cyclization as 
described previously, gave the 7,8-dimethoxy analog 26. 
Compound 26 was determined to be inactive in the luciferase 
reporter assay.  Combined, the lack of activity for 5a, 5b, and 26 
establishes the importance of all three methoxy groups for 
activity. 
Scheme 6. (a) 2-F,5-Cl-PhB(OH)2, Pd(OAc)2, DMSO, 24 h, 90ºC 
(79); (b) NaBH4, EtOH, RT (77%); (c) BrCH2C(O)Cl, Et2O, Et3N, 
0ºC to RT (67%); (d) NaH, THF, RT to reflux (71%). 
Two promising analogs, the quinazolinone (9a) and the 
benzoxazepin-2(3H)-one (19), were evaluated for aqueous 
solubility and stability in mouse microsomes (Figure 3). Both 9a 
and 19 had improved aqueous solubility, 9a had promising 
stability in mouse microsomes although 19 was poor.   
Compound 9a was further characterized in secondary assays.  We 
observed a ~2-fold increase in total SMN protein as well as a 2-
fold increase in the number of gems in SMA derived fibroblasts 
following treatment with 9a.  Consistent with the earlier 
discovery that compound 2 acts in a transcriptional manner,21 
compound 9a increased SMN-luciferase protein expression from 
both the SMN1 and SMN2-luciferase constructs. qRT-PCR 
analysis revealed that compound 9a increased the amount of total 
SMN-luciferase reporter transcripts with a corresponding 
increase in the amount of exon 7 included transcripts. This effect 
required 24 hours for full activation and is consistent with the 
hypothesis that this series is regulating SMN2 expression at the 
transcriptional level. 
Figure 3.  Solubility and stability of 9a and 19. 
Compound 9a was next tested in a preliminary study in SMN∆7 
mice.  Animals were injected with 20 mg/kg of compound 9a in 
DMSO by intraperotineal injection once daily starting on PND 2.  
Compound 9a gave a significant increase in lifespan (e.g., 15-day 
median survival) compared to vehicle treated animals (e.g., 6-day 
median survival).  Compound 9a treated animals also displayed 
an increase in the ability to right themselves when compared to 
vehicle treated animals. 
Racemic 9a was next separated by supercritical fluid 
chromatography, using a ChiralPak IC column, into its two 
individual enantiomers in > 99% enantiomeric excess. Testing of 
the individual enantiomers revealed that the fastest eluting 
enantiomer was inactive, whereas the second enantiomer retained 
all activity in the SMN2 luciferase reporter assay (EC50 = 1.3 
µM, 185%). 
In summary, we established preliminary SAR of the 
quinazolinone series and discovered that most changes to the aryl 
ring substituents led to a loss in activity. We discovered several 
alternative cores (e.g., quinazolinone the benzoxazepin-2(3H)-
one) that had similar or better activity than 2 and the SAR of the 
aryl ring was expanded. Compound 9a was identified as a more 
active analog with improved solubility and stability in mouse 
microsomes.  In an efficacy study in SMN∆7 mice, a 2-fold 
extension in survival was observed following daily treatment 
with 9a.  The synthesis, determination of absolute 
stereochemistry and biological evaluation of single enantiomers 
of 9a and related analogs is in progress and will be reported in 
due course. 
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